Summary of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings

May 17, 2018 - By Don Salinas

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Corporate Logo
During 2017 Q4 the big money sentiment increased to 3. That’s change of 2.21, from 2017Q3’s 0.79. 6 investors sold all, 5 reduced holdings as Dicerna Pharmaceuticals, Inc. ratio is positive. 15 grew holdings while 18 funds acquired holdings. Funds hold 29.10 million shares thus 180.62% more from 2017Q3’s 10.37 million shares.
Jpmorgan Chase And Com owns 35,423 shs for 0% of their capital. Bridger Mgmt Ltd Liability holds 0.54% or 905,998 shs in its capital. Dimensional Fund Advisors L P holds 18,244 shs. 35 are held by Bank & Trust Of America Corp De. Royal Bancorporation Of Canada has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 1,016 shs. Ecor1 Cap Ltd has invested 4.92% of its capital in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Cormorant Asset Mngmt Limited Co stated it has 3.66M shs or 3.46% of all its holdings. Deutsche Savings Bank Ag reported 0% stake. Eam Investors Ltd Liability Co has 64,340 shs. California Employees Retirement System accumulated 41,000 shs or 0% of the stock. New York-based 683 Cap Mgmt Ltd Liability Co has invested 0.42% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Barclays Public Ltd Company invested in 0% or 21,478 shs. Millennium Ltd Llc holds 0% or 66,907 shs in its capital. Camber Capital Limited Liability holds 0.44% or 1.00 million shs in its capital. Adage Cap Prtnrs Group Limited reported 1.98M shs or 0.04% of all its holdings.

Dicerna Pharmaceuticals, Inc. registered $1.57 million net activity with 1 insider purchase and 4 insider sales since December 18, 2017. On Monday, March 19 $13,455 worth of stock was sold by Weissman James B. Brown Bob D had sold 9,669 shs worth $145,035.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings Coverage

A total of 8 analysts rate Dicerna Pharmaceuticals (NASDAQ:DRNA) as follows: 4 “Buy”, 4 “Hold” and 0 “Sell”. Тherefore 50% are bullish. (NASDAQ:DRNA) has 8 ratings reports on May 17, 2018 according to StockzIntelligence. On Tuesday, March 27 the firm has “Hold” rating by FBR Capital given. On Monday, February 5 the firm has “Buy” rating given by SunTrust. On Friday, March 23 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Neutral” rating by H.C. Wainwright. On Wednesday, April 11 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Buy” rating given by Cowen & Co. On Friday, March 9 the firm has “Hold” rating given by Chardan Capital Markets. On Friday, March 9 Stifel Nicolaus maintained the shares of DRNA in report with “Buy” rating. Listed here are Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) PTs and latest ratings.

11/04/2018 Broker: Cowen & Co Rating: Buy Initiate
28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $10 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $10.0000 Initiate
23/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral Old Target: $7 Downgrade
09/03/2018 Broker: Chardan Capital Markets Rating: Hold Initiate
09/03/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $10 New Target: $17 Maintain
05/02/2018 Broker: SunTrust Rating: Buy New Target: $13.0 Initiate
16/01/2018 Broker: Evercore Rating: Outperform New Target: $14 Initiates Coverage On

DRNA is reaching $13.76 during the last trading session, after decreased 0.04%.Currently Dicerna Pharmaceuticals, Inc. is uptrending after 274.53% change in last May 17, 2017. DRNA has also 29,107 shares volume. DRNA outperformed the S&P 500 by 262.98%.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally.The firm is valued at $712.73 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases.Currently it has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

More recent Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news were posted by Streetinsider.com, Benzinga.com and Businesswire.com. The first one has “Dicerna Pharmaceuticals (DRNA) PT Raised to $18 at Stifel” as a title and was posted on May 15, 2018. The next is “Earnings Scheduled For May 14, 2018” on May 14, 2018. And last was posted on May 14, 2018, called “Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update”.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.